AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03235973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine-Cladribine-Busulfan conditioning regimen
Description: Conditioning regimen will be performed from day -6 to day -2 and contains:~* Fludarabine 10 mg/m²/d during 5 days (day-6 to day-2).~* Cladribine during 5 days (day-6 to day-2) at one the following define dose level:~  * Dose 1: 10 mg/m²/d~ * Dose 2: 15 mg/m²/d~ * Dose 3: 20 mg/m²/d~ * Dose 4: 25 mg/m²/d~* IV busulfan will be given on day-6 using fixed dose as following:~  * If age ≤ 60 years: starting dose of 130 mg/m²~ * If age > 60 years: starting dose of 100 mg/m² No busulfan will be administered at day-5, allowing the pharmacokinetic (PK) analyses . Subsequent infusion of IV busulfan will be performed from day-4 to day-2 at the dose recommended by PK analyses
Study NCT03757741 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac imaging tests
Description: 2D transthoracic echocardiography; Late gadolinium-enhancement cardiac magnetic resonance with the evaluation of pulmonary veins anatomy, atrial fibrosis, atrial volumes and the amount of epicardial fat will
Study NCT03757741 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood samle collection
Description: Venous blood sample collection 1 day prior to the ablation procedure: Serum levels of high sensitive C Reactive Protein, Matrix metalloproteases, Interleukin-6, and N-Terminal Pro-B-Type Natriuretic Peptide.
Study NCT02413879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CleanCision
Description: Wound protection during colorectal surgery.
Study NCT01308580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone (or Prednisolone)
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study NCT00374842 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: GlaxoSmithKline Biologicals' licensed influenza vaccine
Study NCT02149537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Study NCT04075045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellth Smartphone App
Description: Patients will receive the app that provides reminders to adhere to their self-care regimen and ability to track their daily adherence via photos of the self-care related items (medications, blood pressure cuff, meals).
Study NCT00374842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1247446A
Description: Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine
Study NCT01629329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin, Acetaminophen, Caffeine pills
Description: One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
Study NCT01629329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine 10mg
Description: One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
Study NCT03871647 — intervention group
Intervention type: DRUG
Intervention: Beta blocker
Description: perioperative beta blockers
Study NCT01365000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Formulation 1
Description: Oral dose, 25 mg
Study NCT01365000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Formulation 2
Description: Oral dose, 25 mg
Study NCT01365000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Formulation 3
Description: Oral dose, 25 mg
Study NCT01365000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Formulation 1a
Description: Oral dose, 25 mg
Study NCT01365000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR118 Formulation 3a
Description: Oral dose, 25 mg
Study NCT02983578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danvatirsen
Description: Given IV
Study NCT02983578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT02899728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02899728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO
Study NCT02899728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study NCT02899728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02899728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02899728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT04674345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity (dose range, 200-800 mg daily).
Study NCT04602624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: SAGE-718 oral tablets.
Study NCT02076464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StudentBodies - Eating Disorders
Description: The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.
Study NCT02222220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: 30 mg/day during 4 weeks
Study NCT02222220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide
Description: 30 mg/day during 4 weeks
Study NCT02222220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT02222220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02322944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality improvement strategies and tools
Description: Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.
Study NCT02322944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process optimization
Description: Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)
Study NCT01371318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Wound Electronic Medical Record
Description: Online Wound Electronic Medical Record is a medical informatics tool that synthesizes data about complex wound problems from multiple sources and is innovative in its capability to performing these critical tasks: i) identification of the information needed to make treatment decisions at the point of care in real time ii) use intelligent search and report features to identify patients who require emergency interventions, and iii) provide evidence-based clinical decision support to clinicians
Study NCT01895465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slitted diaper
Description: A diaper where a slit is made through which a urine collection bag is pulled through
Study NCT02433353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Description: Serotonin norepinephrine reuptake inhibitor
Study NCT02433353 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: EMDR
Description: psychotherapy
Study NCT02433353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: psychotherapy
Study NCT02433353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Look-alike venlafaxine XR tablets containing no active drug
Study NCT04075045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Incentives
Description: Participants may earn up financial rewards tied to their adherence. The rewards are only usable at pharmacies.
Study NCT04075045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Restricted Incentives
Description: Participants may earn up financial rewards tied to their adherence. The rewards are only usable at most stores, except for prohibited purchases such as alcohol, tobacco, or firearms, and is not redeemable for cash.
Study NCT02312531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B immunoglobulin
Description: Hepatitis B immunoglobulin 200 IU injection at gestational week 20, 24, 28, 32, 34, 36, 38, 39, and 40 in HBIG group mothers.
Study NCT00802776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond laser assisted keratoplasty
Study NCT00802776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PKP
Study NCT04596462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of SAPHO by PET/CT.
Study NCT04948385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: deep sedation with propofol +/- adjuvants such as midazolam, sufentanil, lidocaine and/or dehydrobenperidol
Study NCT04948385 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: No sedation
Description: No sedation
Study NCT01057160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Description: use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
Study NCT01057160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rizatriptan
Description: use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
Study NCT03053193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MammaPrint, BluePrint, and Full-Genome Testing
Description: Agendia will run MammaPrint and BluePrint tests using the full genome testing array.
Study NCT04247594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: synthetic small molecule supplied as 500 mg tablets
Study NCT03105882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-Spinal Scaffold
Description: Experimental: Neuro-Spinal Scaffold
Study NCT04281654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Social Conversation
Description: Active Social Conversation
Study NCT04281654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Social Conversation
Description: Active Social Conversation
Study NCT03799094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Participants will receive intravenous vitamin C therapy at the indicated dose.
Study NCT03799094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor
Description: Participants will receive Tyrosine kinase inhibitor therapy in cycles: continuous treatment at the indicated dose.
Study NCT00937599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brazil Nut
Description: During 16 weeks the adolescents consumed 3-5 nuts/day
Study NCT02367729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulator
Description: Non-invasive, battery operated neurostimulator of the external ear worn for 5 days each week x 4 weeks.
Study NCT02367729 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Inactive neurostimulator device pre-programmed to be inactive. To be worn for 5 days each week x 4 weeks.
Study NCT02421107 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glysure CGM
Study NCT02421107 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: iStat intermittent testing
Study NCT04265456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 100mg
Description: Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
Study NCT04265456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1300mg
Description: Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
Study NCT02726373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: type of walking
Description: Subjects walked either intermittently or continuously twice a week for 4 weeks, then crossed over
Study NCT02726373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: type of walking
Description: Subjects walked either intermittently or continuously twice a week for 4 weeks, then crossed over
Study NCT02009982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation
Description: Catheter Ablation of Vagal Inputs in Left Atrium
Study NCT02009982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
Description: This is the device that will be used to perform the Cardioneuroablation procedure
Study NCT01891786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management Intervention
Description: The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk
Study NCT01891786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk Result
Description: Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.
Study NCT02953262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Brochure
Description: Participants will receive a mailed brochure with basic My HealtheVet content.
Study NCT02953262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Training Guide for Veterans Living with Diabetes
Description: Participants will be mailed a bound My HealtheVet training guide with step by step instructions on how to register, upgrade to Premium account, refill prescriptions, use secure messaging, download their Blue Button reports, and other features
Study NCT02953262 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: My HealtheVet Group Training
Description: Participants will be invited to participate in a scheduled group training to learn how to use My HealtheVet to help manage their diabetes
Study NCT02953262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Group Training
Description: Participants will be invited to participate in a scheduled group training to learn how to use My HealtheVet to help manage their diabetes
Study NCT02953262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Individual Training
Description: Participants will be invited to participate in a one-on-one training to learn how to use My HealtheVet to help manage their diabetes at a time of their convenience.
Study NCT01432782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 4 ml
Study NCT01432782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline
Study NCT00666718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: patient glucose-level dependent, injection, once daily in the evening, 24 weeks
Study NCT00666718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Protamine Suspension (ILPS)
Description: patient glucose-level dependent, injection, once daily in the evening, 24 weeks
Study NCT00666718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: subcutaneous injections prior to meals, 24 weeks
Study NCT00666718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: subcutaneous injections prior to meals, 24 weeks
Study NCT01863095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback and Exercise
Study NCT01863095 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Feedback and Exercise
Study NCT00159081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol, Risperidone (drug)
Description: targeted dose of 2-4 mg/day over 1 year
Study NCT00159081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol, Risperidone (drug)
Description: targeted dose of 2-4 mg/day over 1 year
Study NCT02935946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Liquid Barium
Description: Cold Liquid is defined as being between 4-9 °C. One liter bottles of Poland Spring Natural Spring Water will be kept in the radiology suite to remain at room temperature. As described by Fink and colleagues,(42) the bottled water will be used to mix the barium powder to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula. After the barium is prepared, 2oz will be poured into a bottle and placed in a refrigerator set to 36°F; this will allow the barium to cool to approximately 4-9°C. Before oral administration, the barium mixture will be measured with a thermometer (TP3001 Digital Thermometer from Red Lantern®) to document the exact temperature.
Study NCT00872365 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Regular aerobic physical exercise
Description: Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.
Study NCT00872365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Micronutrients
Description: Zinc 30mg, Magnesium 400mg, Beta-carotene 9 mg, Tocopherol 30mg, vitamin C 200mg y Niacin 100mg.
Study NCT00872365 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Activities of daily living + placebo
Description: Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist and prenatal care.~Placebo Comparator: Equivalent to placebo (maltodextrin).
Study NCT00776269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: argon laser and radiofrequency
Study NCT03719261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chitosan nanoparticles
Description: Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
Study NCT03719261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hypochlorite
Description: Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
Study NCT01039584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butoconazole Nitrate Vaginal Cream
Description: vaginal cream
Study NCT01039584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vaginal cream
Study NCT01039584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gynazole 1 vaginal cream
Description: vaginal cream
Study NCT04156282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: knot burial technique
Description: surgical suturing intervention
Study NCT04156282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classical closure
Description: surgical suturing intervention